Mining and Analysis of the Formulation Rules of Chinese Patent Medicine for Cold Based on 2015 Edition of Chinese Pharmacopeia（Part Ⅰ） / 中国药房

ABSTRACT

OBJECTIVE： To mine and analyze the formulation rules of Chinese patent medicine for cold， and to provide reference for clinical dialectical medication and R&D of new medicine for cold. METHODS： The name， dosage form， formulation， function of curing of Chinese patent medicines for cold were collected from 2015 edition of Chinese Pharmacopeia （part Ⅰ） and then input into TCM Inheritance Assistant Platform V 2.5； use frequency of TCM were counted. Apriori algorithm and association rules were used to analyze the core medicinal material combination （10％ support and 0.65 confidence）. New formulation combinations were extracted by unsupervised entropy hierarchical clustering method. RESULTS： A total of 130 kinds of Chinese patent medicine （196 Chinese patent medicine with the same prescription and different dosage forms） for treating cold were collected， including granules （47）， pills （32）， tablets （31）， mixtures （31）， etc. 264 medicinal materials were involved. The cold syndromes contained wind-heat syndrome， wind-cold syndrome， summer-dampness syndrome and Qi deficiency syndrome. Top 3 medicinal materials in the list of use frequency were Glycyrrhiza uralensis （45.38％）， Scutellaria baicalensis （32.31％） and Platycodon grandiflorus （31.54％）. There were 28 core medicinal material combinations， among which the top 3 were               G. uralensis-P. grandiflorus，  Mentha haplocalyx-P. grandiflorus and S. baicalensis-Forsythia suspensa. New combinations were excavated， including Nepeta cataria-P. grandiflorus-M. haplocalyx-Citrus reticulate-Folium Perillae-Citrus aurantium- Poria cocos， F. suspense-S. baicalensis-Lonicera japonica- Arctium lappa-Fermented soybean. CONCLUSIONS： This study analyzed the formulation rules of Chinese patent medicine for treating cold by using the TCM inheritance assistant platform V2.5， which can provide reference for clinical dialectical medication and R&D of new medicines for cold.